AE-M

Drug Profile

AE-M

Alternative Names: AE-08; AE-08 vaccine; AE-M vaccine; Ii-key/gp100

Latest Information Update: 21 Apr 2016

Price : $50

At a glance

  • Originator Antigen Express
  • Class Cancer vaccines; Peptide vaccines
  • Mechanism of Action Helper-inducer T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma

Most Recent Events

  • 21 Apr 2016 Phase I development is ongoing in USA
  • 03 Dec 2012 Phase I clinical trials in Malignant melanoma in USA (Parenteral)
  • 24 May 2011 Melanoma vaccine is still in preclinical trials for Malignant melanoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top